These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 30690950)

  • 1. A Report of Rabbit Syndrome Who Benefited from Sigma 1 Agonist Fluvoxamine.
    Albayrak Y; Beyazyüz M; Abbak Ö; Altındağ E
    Clin Psychopharmacol Neurosci; 2019 Feb; 17(1):134-138. PubMed ID: 30690950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefical effects of sigma-1 agonist fluvoxamine for tardive dyskinesia and tardive akathisia in patients with schizophrenia: report of three cases.
    Albayrak Y; Hashimoto K
    Psychiatry Investig; 2013 Dec; 10(4):417-20. PubMed ID: 24474992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beneficial effects of the sigma-1 agonist fluvoxamine for tardive dyskinesia in patients with postpsychotic depressive disorder of schizophrenia: report of 5 cases.
    Albayrak Y; Hashimoto K
    Prim Care Companion CNS Disord; 2012; 14(6):. PubMed ID: 23585988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The opposite effects of fluvoxamine and sertraline in the treatment of psychotic major depression: a case report.
    Kishimoto A; Todani A; Miura J; Kitagaki T; Hashimoto K
    Ann Gen Psychiatry; 2010 May; 9():23. PubMed ID: 20492642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluvoxamine for aripiprazole-associated akathisia in patients with schizophrenia: a potential role of sigma-1 receptors.
    Furuse T; Hashimoto K
    Ann Gen Psychiatry; 2010 Mar; 9():11. PubMed ID: 20205742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can the sigma-1 receptor agonist fluvoxamine prevent schizophrenia?
    Hashimoto K
    CNS Neurol Disord Drug Targets; 2009 Dec; 8(6):470-4. PubMed ID: 19702566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluvoxamine for blonanserin-associated akathisia in patients with schizophrenia: report of five cases.
    Furuse T; Hashimoto K
    Ann Gen Psychiatry; 2010 Apr; 9():17. PubMed ID: 20416096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sigma-1 receptor agonist fluvoxamine for delirium in patients with Alzheimer's disease.
    Furuse T; Hashimoto K
    Ann Gen Psychiatry; 2010 Jan; 9():6. PubMed ID: 20148109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluvoxamine monotherapy for psychotic depression: the potential role of sigma-1 receptors.
    Furuse T; Hashimoto K
    Ann Gen Psychiatry; 2009 Dec; 8():26. PubMed ID: 20025739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sigma-1 receptor agonist fluvoxamine for delirium in intensive care units: report of five cases.
    Furuse T; Hashimoto K
    Ann Gen Psychiatry; 2010 Apr; 9():18. PubMed ID: 20416097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sigma-1 receptor agonist fluvoxamine for postoperative delirium in older adults: report of three cases.
    Furuse T; Hashimoto K
    Ann Gen Psychiatry; 2010 Jun; 9():28. PubMed ID: 20573265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypersalivation induced by olanzapine with fluvoxamine.
    Hori T; Makabe K; Nemoto K; Asada T
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jun; 30(4):758-60. PubMed ID: 16574294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cognition and depression: the effects of fluvoxamine, a sigma-1 receptor agonist, reconsidered.
    Hindmarch I; Hashimoto K
    Hum Psychopharmacol; 2010 Apr; 25(3):193-200. PubMed ID: 20373470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antidepressant treatment of psychotic major depression: potential role of the sigma receptor.
    Stahl SM
    CNS Spectr; 2005 Apr; 10(4):319-23. PubMed ID: 15788959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sertraline inhibits nerve growth factor-induced neurite outgrowth in PC12 cells via a mechanism involving the sigma-1 receptor.
    Matsushima Y; Terada K; Kamei C; Sugimoto Y
    Eur J Pharmacol; 2019 Jun; 853():129-135. PubMed ID: 30902656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine.
    Goodman WK; Price LH; Delgado PL; Palumbo J; Krystal JH; Nagy LM; Rasmussen SA; Heninger GR; Charney DS
    Arch Gen Psychiatry; 1990 Jun; 47(6):577-85. PubMed ID: 2112374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sigma-1 receptor agonists as therapeutic drugs for cognitive impairment in neuropsychiatric diseases.
    Niitsu T; Iyo M; Hashimoto K
    Curr Pharm Des; 2012; 18(7):875-83. PubMed ID: 22288409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of the sigma1 receptor in the antidepressant-like effects of fluvoxamine in the forced swimming test in comparison with the effects elicited by paroxetine.
    Sugimoto Y; Tagawa N; Kobayashi Y; Mitsui-Saito K; Hotta Y; Yamada J
    Eur J Pharmacol; 2012 Dec; 696(1-3):96-100. PubMed ID: 23041149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluvoxamine increased glutamate release by activating both 5-HT(3) and sigma-1 receptors in prelimbic cortex of chronic restraint stress C57BL/6 mice.
    Fu Y; Yu S; Guo X; Li X; Li T; Li H; Dong Y
    Biochim Biophys Acta; 2012 Apr; 1823(4):826-37. PubMed ID: 22306004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.